Cullinan Therapeutics (NASDAQ:CGEM) Stock Rating Lowered by Wall Street Zen

Cullinan Therapeutics (NASDAQ:CGEM) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Friday.

Several other research firms have also issued reports on CGEM. New Street Research set a $26.00 target price on shares of Cullinan Therapeutics in a report on Thursday, November 20th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cullinan Therapeutics in a report on Monday, December 29th. Zacks Research raised shares of Cullinan Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday. BTIG Research raised their price objective on shares of Cullinan Therapeutics from $32.00 to $38.00 and gave the company a “buy” rating in a research report on Monday, November 24th. Finally, Wedbush lifted their target price on shares of Cullinan Therapeutics from $25.00 to $34.00 and gave the company an “outperform” rating in a research note on Tuesday, December 9th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $28.71.

Cullinan Therapeutics Stock Performance

Shares of Cullinan Therapeutics stock opened at $12.50 on Friday. The stock has a market cap of $738.45 million, a P/E ratio of -3.78 and a beta of -0.09. The stock’s fifty day moving average is $10.71 and its 200 day moving average is $8.56. Cullinan Therapeutics has a one year low of $5.68 and a one year high of $13.33.

Cullinan Therapeutics (NASDAQ:CGEM) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.95) by $0.18. Analysts predict that Cullinan Therapeutics will post -3.04 EPS for the current year.

Insider Activity

In related news, CEO Nadim Ahmed sold 9,922 shares of the firm’s stock in a transaction on Tuesday, December 23rd. The shares were sold at an average price of $10.01, for a total transaction of $99,319.22. Following the completion of the transaction, the chief executive officer directly owned 420,699 shares of the company’s stock, valued at approximately $4,211,196.99. This trade represents a 2.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Jennifer Michaelson sold 4,000 shares of the business’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $12.30, for a total transaction of $49,200.00. Following the completion of the sale, the insider owned 128,635 shares in the company, valued at approximately $1,582,210.50. The trade was a 3.02% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 33,420 shares of company stock valued at $356,082 in the last quarter. Company insiders own 7.16% of the company’s stock.

Institutional Investors Weigh In On Cullinan Therapeutics

A number of hedge funds have recently made changes to their positions in CGEM. Rafferty Asset Management LLC grew its holdings in Cullinan Therapeutics by 3.8% during the 3rd quarter. Rafferty Asset Management LLC now owns 40,729 shares of the company’s stock valued at $242,000 after buying an additional 1,503 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Cullinan Therapeutics by 44.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,182 shares of the company’s stock valued at $62,000 after acquiring an additional 2,523 shares during the last quarter. Rhumbline Advisers boosted its position in shares of Cullinan Therapeutics by 3.9% during the 2nd quarter. Rhumbline Advisers now owns 74,105 shares of the company’s stock valued at $558,000 after acquiring an additional 2,767 shares during the last quarter. Tema Etfs LLC grew its holdings in shares of Cullinan Therapeutics by 9.0% in the second quarter. Tema Etfs LLC now owns 42,692 shares of the company’s stock valued at $321,000 after purchasing an additional 3,528 shares in the last quarter. Finally, Signaturefd LLC increased its position in Cullinan Therapeutics by 689.7% in the fourth quarter. Signaturefd LLC now owns 4,130 shares of the company’s stock worth $43,000 after purchasing an additional 3,607 shares during the last quarter. 86.31% of the stock is currently owned by hedge funds and other institutional investors.

Cullinan Therapeutics News Summary

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: Zacks upgraded Cullinan from “hold” to “strong-buy,” which can attract momentum and retail flows into the shares. Zacks Research Upgrade
• Positive Sentiment: Technical/momentum coverage notes a big jump in the stock’s Relative Strength (RS) rating to 91 — a sign some quant/momentum-focused investors may increase exposure. Stocks to watch: Cullinan Therapeutics sees RS rating jump to 91
• Neutral Sentiment: Coverage pieces outline what could sustain recent price strength (pipeline progress and upcoming clinical data), but they frame these as potential catalysts rather than confirmed drivers — meaning upside depends on execution. Here’s What Could Help Cullinan Therapeutics (CGEM) Maintain Its Recent Price Strength
• Neutral Sentiment: Analyst-comment roundup / industry insight coverage mentions Cullinan among healthcare names discussed by market analysts; useful context but no single analyst note in that article moved the story materially. Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM)…
• Negative Sentiment: A sell-side downgrade by Wall Street Zen to a “sell” rating adds downside pressure and may prompt cautious positioning from some investors. Cullinan Therapeutics (NASDAQ:CGEM) Downgraded to Sell Rating by Wall Street Zen
• Negative Sentiment: Insider Jennifer Michaelson sold 4,000 shares (about $49k at the transaction price), a continuation of prior small sales; while not large versus total insider holdings, repeated insider sales can be interpreted negatively by some investors. Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells $49,200.00 in Stock

About Cullinan Therapeutics

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.